Croda Pharma launches a new bioprocessing solution for shear stress in mammalian cell culture

PRESS RELEASE

18 Oct 2024: Croda Pharma has announced the launch of Super Refined™ Poloxamer 188, an innovative bioprocessing solution developed to meet the increasing demands of biopharmaceutical development. 

The new product was officially launched on October 16th at Festival of Biologics in Basel, Switzerland, where James Humphrey, Research and Technology Specialist at Croda Pharma presented on the latest solution for shear stress in cell culture. 

Super Refined™ Poloxamer 188 has been optimised specifically for mammalian cell culture with tightly controlled impurity profiles and molecular weight, ensuring optimal cell culture performance and batch-to-batch consistency. As a product belonging to the Super Refined™ range, it meets excellent purity standards, undergoes rigorous quality testing, is offered in enhanced packaging, and is also suitable for use as a parenteral excipient in biologic formulations. 

This new addition to Croda Pharma’s established range of highly purified ingredients aims to support the delivery of biologics, addressing critical challenges faced by the industry in the development of advanced therapeutics. 

Katie Dec, Global Business Director, said: 

“We are absolutely thrilled to bring this new bioprocessing solution to our customers. This marks another exciting chapter in our evolution, bringing our deep expertise in purification of ingredients for pharmaceutical applications into the bioprocessing realm.” 

On October 29th, in a collaboration with BioProcess International, Croda Pharma will host a global webinar to introduce the newly launched Super Refined™ Poloxamer 188 and the expanded bioprocessing range.  

With this launch, Croda continues to set new standards in excipient purity and performance, addressing critical challenges in biopharmaceutical development, and reinforcing the commitment to innovation and patient safety in advanced therapeutic formulations. Leveraging its expertise in biotechnology and high purity ingredients, the company is providing a growing range of solutions for bioprocessing, spanning recombinant protein manufacture, viral vector production and more. 

Croda Pharma’s solutions for bioprocessing include ingredients for cell culture, as well as sustainable, compendial detergents for viral inactivation and cell lysis, meeting the needs of end-applications such as the biomanufacture of recombinant protein therapeutics, viral vector-based therapies, plasma-derived or blood fractionation therapies, and more.